In The Market Today: iBio (IBIO), Atossa Genetics (ATOS), Gilead Sciences (GILD), Twitter (TWTR)

iBio Finds Gains On Positive Data


iBio is having a great day in the market today after announcing that Dr. Feghali-Bostwick made a new discovery that proves to be an extension of the doctor’s previous discovery. Dr. Feghali-Bostwick previously found that a peptide derived from endostatin can prevent or ameliorate fibrosis as determined by lung histology and hydroxyproline content in a widely accepted animal model of the disease. The new information announced today demonstrates that E4 can be dosed orally and has the ability to prevent or modify the disease in either a single or repeat-dose administration regimen. This is the first time that an orally-dosed peptide has proven to be effective in treating fibrosis in any animal. As a result of the positive news, IBIO is currently (2:30) trading at $0.70 per share after a gain of 3.31%.

Atossa Genetics Climbs On FDA Acceptance Of Investigational Drug

Atossa Genetics Inc (NASDAQ: ATOS)

Atossa Genetics is climbing in the market today after receiving a response to its application with the FDA for Fulvestrant. Fulvestrant is an investigational drug that is expected to be a positive treatment for women with breast cancer. Recently, ATOS submitted the Investigational NDA with the FDA for a clinical trial designed to test the effectiveness of the drug in women with DCIS (Ductal Carcinoma in Situ). As a result of the FDA’s acceptance of the application, ATOS will be proceeding with an open-label, non-randomized pharmacokinetic and safety study of Fulvestrant. Following the announcement of the news ATOS is having a great day in the market today, currently (2:42) trading at $0.92 per share after a gain of 12.32%.

Gilead Sciences Produces Positive Data

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead Sciences produced data from four Phase III clinical studies known as ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4. The studies evaluated a once-daily, fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir with an investigational pangenotypic NS5 inhibitor known as velpatasvir. The combination treatment was designed for genotype 1-6 chronic hepatitis C virus infection. While the news released was overwhelmingly positive, Hillary Clinton’s comments today with regard to the cost of specialty treatments sent GILD down in the market. Nonetheless, I am expecting to see a recovery relatively soon. Currently (2:47), GILD is trading at $105.04 per share after a loss of 3.14% so far today.

Twitter Continues To Struggle To Find A CEO

Twitter Inc (NYSE: TWTR)

Twitter is having yet another rough day in the market today as investors continue to wonder how long it will take for the company to find a new CEO. The reality is that the search is harder than one would imagine. I wrote in depth about why it’s taking so long here. In short, Dorsey simply doesn’t have the time to be a permanent CEO and with a struggling company andĀ finding someone that’s both qualified and willing to take on the role is proving to be incredibly difficult. TWTR is currently (1:49) trading at $27.38 per share after a loss of 2.07% so far today.

[Image Courtesy of Fairview High School]

Leave a Comment